Icatibant, a new drug, has been registered
Mir-Pharm announces successful registration of a new orphan drug.
Moscow, June 2023
Icatibant is a bradykinin B2-receptor blocker, an anti-allergic drug used for symptomatic treatment of acute attacks of hereditary angioedema in adults with C1 esterase inhibitor deficiency.
Icatibant has been recognised in a number of countries as an orphan drug - that is, a drug for the treatment of rare diseases, which a priori can not give a great effect in pharmacology due to the narrowness of use.
Bradykinin is a peptide-based hormone that is locally produced in tissues, very often in response to injury. It increases vascular permeability, dilates blood vessels and causes contraction of smooth muscle cells. Bradykinin plays an important role as a mediator of pain. Excess bradykinin is responsible for typical symptoms of inflammation such as oedema, redness, overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor. Little is known about the effect of icatibant on the bradykinin B1 receptor.
Each ml of solution contains 10.00 mg of icatibant (10.43 mg icatibant acetate). Each pre-filled 3 ml syringe contains 30 mg ikatibant (31.29 mg ikatibant acetate). Excipients to be considered in the composition of the medicinal product: sodium chloride, sodium hydroxide.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.